Literature DB >> 2814896

Digital defects induced by vasodilating agents: relationship to reduction in uteroplacental blood flow.

B R Danielsson1, S Reiland, E Rundqvist, M Danielson.   

Abstract

The effects of nifedipine (40-100 mumol/kg), nitrendipine (40 and 80 mumol/kg), hydralazine (381 and 763 mumol/kg), felodipine (12 mumol/kg), and the pharmacologically inactive first-step metabolite of felodipine, H152/37 (80 mumol/kg) were studied in rabbits (New Zeeland White) after oral administration on day 16 of gestation. The vasodilating drugs--nifedipine, nitrendipine, felodipine, and hydralazine--all induced digital defects in the fetuses. The defects consisted of a reduction, absence, or abnormal structure of the distal phalanx of especially the fourth digit on the hind paw(s). Histologically, a disturbed differentiation of the cartilage, and secondarily also of the ossification centre and joint structure of the distal phalanx, was observed. In contrast, no digital abnormalities were observed after administration of vehicle or H152/37. The findings that vasodilators with different structures, like dihydropyridines and hydralazine, induced the same type of digital defects strongly suggest that the observed phalangeal defects are secondary to pharmacological action, and not related to chemical structure. A decrease in uteroplacental blood flow, caused by excessive hypotension, is discussed as the most probable mechanism underlying the observed defects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2814896     DOI: 10.1002/tera.1420400407

Source DB:  PubMed          Journal:  Teratology        ISSN: 0040-3709


  8 in total

Review 1.  Voltage-dependent calcium channels in chondrocytes: roles in health and disease.

Authors:  Csaba Matta; Róza Zákány; Ali Mobasheri
Journal:  Curr Rheumatol Rep       Date:  2015-07       Impact factor: 4.592

2.  L-type voltage-gated Ca2+ channel CaV1.2 regulates chondrogenesis during limb development.

Authors:  Yuji Atsuta; Reiko R Tomizawa; Michael Levin; Clifford J Tabin
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-07       Impact factor: 11.205

3.  Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy.

Authors:  Robert L Davis; David Eastman; Heather McPhillips; Marsha A Raebel; Susan E Andrade; David Smith; Marianne Ulcickas Yood; Sascha Dublin; Richard Platt
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-11-15       Impact factor: 2.890

Review 4.  Effects of antihypertensive drugs on the unborn child: what is known, and how should this influence prescribing?

Authors:  S M Khedun; B Maharaj; J Moodley
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

Review 5.  Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy.

Authors:  E Rey; J LeLorier; E Burgess; I R Lange; L Leduc
Journal:  CMAJ       Date:  1997-11-01       Impact factor: 8.262

Review 6.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

7.  Maternal vasoactive exposures, amniotic bands, and terminal transverse limb defects.

Authors:  Martha M Werler; Jaclyn L F Bosco; Stuart K Shapira
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2009-01

Review 8.  Hypertension in pregnancy: natural history and treatment options.

Authors:  L Foo; J Tay; C C Lees; C M McEniery; I B Wilkinson
Journal:  Curr Hypertens Rep       Date:  2015-05       Impact factor: 5.369

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.